Baby-hamster kidney (BHK) cells were labelled with [2-3H]mannose for 1-2 days in media containing 1-deoxynojirimycin, N-methyl-l-deoxynojirimycin or 1-deoxymannojirimycin. Glycopeptides obtained by Pronase digestion of disrupted cells were analysed by lectin affinity chromatography, by Bio-Gel P4 gel filtration and by paper chromatography of oligosaccharides released by endo-fl-N-acetylglucosaminidase H.
INTRODUCTION
Inhibitors of specific steps in assembly of asparaginelinked oligosaccharides (N-glycans) are useful reagents to study the metabolic pathways of protein glycosylation and the biological roles of the sugar moieties of glycoproteins [1, 2] . Previously we have examined the effects of swainsonine, an inhibitor of mannosidase II, on processing of N-glycans in BHK cells [3] . Incubation of the cells with swainsonine was found to induce a complete switch from assembly of complex-type N-glycans normally present to hybrid-type chains containing five mannose residues and NeuNAca2-*3Galfl1-. 4GlcNAcfll-,2/4 sequences attached to the Manol->3-linked residue of the core. Similar structures were identified in ricin-resistant mutants of BHK cells deficient in mannosidase II [4] . These results showed that under normal growth conditions BHK cells do not utilize alternative pathways independent of mannosidase II [5] [6] [7] for conversion of oligomannosetype chains into complex-type carbohydrate units.
In the present paper we report on the effects of other inhibitors of processing reactions on glycoprotein synthesis in BHK cells. and N- methyl-l-deoxynojirimycin (M-dNM) are analogues of D-glucose that inhibit competitively the processing enzymes glucosidases I and II [8] [9] [10] . 1-Deoxymannojirimycin (dMM), an analogue of D-mannose, is an inhibitor of some processing mannosidases [11] [12] [13] . Other studies with these inhibitors have used as probes of glycosylation, virally infected cells [1 1,13-15] and glycoproteins secreted by inhibitor-treated cells [8, [16] [17] [18] . The systems are selective in the sense that assembly of mature infective virus or secretion of glycoproteins may require glycoproteins bearing a normal complement of asparagine-linked oligosaccharides and may underestimate the effect of processing inhibitors on bulk protein glycosylation. Therefore we have examined the effects of dNM, M-dNM and dMM on protein glycosylation in BHK cells under conditions used previously [3] for swainsonine. We show that complex-type chains are present even when the cells are cultured for prolonged periods in medium containing the inhibitors.
EXPERIMENTAL

Materials
Materials were obtained as follows: concanavalin A-Sepharose and lentil lectin-Sepharose from Pharmacia; Bio-Gel P2 (100-200 mesh) and Bio-Gel P4 (< 400 mesh) from Bio-Rad Laboratories; Pronase CB and jack-bean ax-mannosidase from Calbiochem-Behring; endo-,f-N-acetylglucosaminidase H from Miles Laboratories; methyl a-glucoside and methyl a-mannoside from Sigma Chemical Co.; [2-3H] mannose (13.4 Ci/mmol) and [35S]methionine (1.34 Ci/mmol) from Amersham International. dNM was a gift from Bayer A.G., WuppertalElberfeld, Germany; M-dNM was prepared by Nmethylation of dNM [2] ; dMM was synthesized as described previously [11] ; castanospermine from seeds of Castanosperum australe was provided by Dr B. Winchester, London, U.K. Each inhibitor was stored at 2°C as 2 mg/ml solutions in water and sterilized by passage through 0.22 ,um-pore-size Millipore filters.
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Cell cultures BHK cells were grown routinely in monolayer culture at 37°C in Eagle's medium (Gibco, Paisley, Scotland, U.K.) containing 22 mM-glucose and supplemented with 10 % (v/v) foetal-calf serum, penicillin and streptomycin.
Cell monolayers were trypsinized and re-seeded at 1:4 dilutions for further growth. For treatment of cell cultures with inhibitors, cells were grown in 100 mmdiameter plastic tissue-culture dishes containing 10 ml of a modified Eagle's medium containing 5 mM-glucose and supplemented as described above. The cells were grown to touching confluency before addition of inhibitor to the required concentration. After a further period of incubation to allow the inhibitors to take effect,
[3H]mannose was added to give 2-10 lCi/ml and the cells were incubated for 24-48 h at 37 'C. The inhibitors were present during the labelling period. Preparation of glycopeptides Cells in monolayer cultures were washed with phosphate-buffered saline (0.15 M-NaCl/50 mM-sodium phosphate buffer, pH 7.2), harvested by scraping and digested with Pronase [19] . Washed cell pellets were suspended in 10 mM-CaCl2/0.02 % NaN3/50 mM-Tris/ HCI buffer, pH 7.5 (0.5 ml), and heated at 90 'C for 5 min. Pronase solution (0.4 % in the above buffer) was added in 50 ,u portions each day for 2-3 days during incubation at 37 'C. The digests were again heated to inactivate Pronase and centrifuged at 10000 g for 10 min. At least 85 % of total radioactivity incorporated into acid-precipitable cellular proteins was recovered in the supernatants after Pronase digestion. Column chromatography Glycopeptide solutions (0.5 ml or less) were applied at room temperature to columns (3-ml bed volume) of concanavalin A-Sepharose mounted in a multiplecapacity frame. After application of glycopeptides, the columns were sealed and kept for 1 h to allow maximal binding of glycopeptides. Then 1 ml fractions were collected manually by elution [19] first with 1 mM-CaCl2/ 1 mM-MgCl2/ 1 mM-MnCl2/0.02 % NaN3/ 10 mM-Tris/ HCI buffer, pH 7.5 (10 ml), followed by 10 mM-methyl a-glucoside (10 ml) and 500 mM-methyl a-mannoside (10 ml) in the same buffer. Samples of column fractions were taken for counting of radioactivity. Up to six glycopeptide mixtures could conveniently be analysed simultaneously by this procedure. Appropriate column fractions were pooled, concentrated by rotary evaporation and desalted by passage through a column (2 cm x 27 cm) of Bio-Gel P2. Fractions (2 ml) eluted with water were collected, and peak radioactive fractions were dried and reconstituted in water (0.5 ml). Affinity chromatography of glycopeptides (0.5 ml or less) on lentil lectin-Sepharose column (3 ml bed volume) was performed [19] as described for concanavalin ASepharose chromatography except the elution employed first buffer (10 ml) followed by 200 mM-methyl aglucoside in buffer (10 ml Lectin toxicity Cells grown in control medium or in media containing 2 mM-dNM, -dMM or -castanospermine were trypsinized, seeded on 35 mm-diameter dishes and grown to confluency in media supplemented as above. The growth medium was then removed and replaced with either ricin or modeccin (0-100 #g/ml) in serum-free medium (1 ml) with or without glycosylation inhibitors. After incubation at 37°C for 3 h the cells were labelled for 1 h at 37°C with [35S]methionine (0.1 ml, 20 ,tCi). Incorporation of radioactivity into acid-precipitable material was measured as described previously [3] .
RESULTS
Concanavalin A-Sepharose chromatography of
I3Hlmannose-labelled glycopeptides Glycopeptides obtained from BHK cells by Pronase digestion after metabolic labelling with [3H]mannose were separated into three fractions by chromatography on concanavalin A-Sepharose (Fig. 1) . Fraction A eluted with buffer contains tri-and tetra-antennary complex-type glycopeptides, fraction B eluted with 10 mMmethyl a-glucoside contains bi-antennary complextype glycopeptides, and fraction C eluted with 500 mMmethyl ac-mannoside contains oligomannose-type and hybrid-type glycopeptides [3, 19, 21, 22] . All three fractions werFe ob,tained from BHK cells treated with I mm-dNM ( Fig. 1 a) , 1 mM-M-dNM ( Fig. 1 b) The relative amounts of radioactivity recovered in fractions A (V), B (A) and C (0) from concanavalin A-Sepharose (see Fig. 1 Bio-Gel P4 fractions from Fig. 4 were subjected to paper chromatography for various times. The paper was cut into 1 cm strips and each strip was eluted with 1 ml of water. Samples were counted for radioactivity. (a)-(c) Bio-Gel P4 fractions 1, 2 and 3 respectively from cells treated with dNM (Fig. 4a) ; (d)-(e) Bio-Gel P4 fractions 1 and 2 respectively from cells treated with MdNM (Fig. 4b) ; (j)-(g) Bio-Gel P4 fractions 1 and 2 from cells treated with dMM (Fig. 4c) (Fig. 5g) . Oligosaccharide fractions 1 and 2 were digested completely by jack-bean a-mannosidase to free mannose and a minor component that was eluted in column fractions 88-93, in the position of Man,k1-*4GlcNAc (Fig. 6b) . The recoveries of [3H]mannose radioactivity in these two peaks were in the ratios 7.9: 1 for fraction 1 (Fig. 6b) present. Similar treatment was performed for the complex-type glycopeptides eluted from concanavalin A-Sepharose in fractions A and B (Fig. 1 c) and assumed to contain a trimannosyl core sequence. positions for these components are Glc3Man9GlcNAc, Glc3Man8GlcNAc and Glc3Man7GlcNAc for the following reasons. Treatment of Bio-Gel fraction 1 ( Fig. 4b) with jack-bean a-mannosidase released about 50 % of the label as free mannose and produced modified oligosaccharides that were eluted from Bio-Gel P4 in a major peak and a minor peak representing 54 % and 6 % of total radioactivity respectively (Fig. 6a) . The presence of glucose protects from a-mannosidase action mannose residues substituted on the al-*3-linked mannose unit of the core sequence. The shift in size of the major resistant fragment of fraction 1 oligosaccharides and the proportion of label released as free mannose suggests that removal of three or four mannose units had occurred. The resistant oligosaccharides retained affinity for concanavalin A-Sepharose, as shown by rechromatography, when all of the radioactivity associated with these oligosaccharides was bound and eluted with 500 mM-methyl a-mannoside (results not shown). Evidently the al-->6-linked mannose residue of the core sequence was not removed by jack-bean a-mannosidase, and hence the end products retained two reactive terminal a-mannose residues required for concanavalin A binding. Previously we have reported the resistance of this residue to a-mannosidase in hybrid-type oligosaccharides containing substituents on the al-*3-linked mannose residue of the core sequence [23] . It seems likely from the results that the major mannosidase-resistant oligosaccharide (Fig. 6a ) was Glc3Man5GlcNAc and that the minor resistant oligosaccharide component contained one or two fewer glucose residues. Fraction 2 (Fig. 4b) produced after jack-bean z-mannosidase treatment mainly free mannose and a small peak of Man,f1-4GlcNAc (Fig.   6a ), confirming that it consists largely of nonglucosylated species.
dNM-treated cells. Bio-Gel P4 fraction 3 obtained from dNM-treated cells (Fig. 4a) (Fig. Sb) . Fraction 1 mainly contained two slowly migrating oligosaccharides I and II (Fig. 5 a) .
From their migration relative to Man9GlcNAc on paper chromatography, oligosaccharides I-III probably contain one to three additional hexose units. Evidence that these components and oligosaccharide IV represent glucosylated MannGlcNAc species containing variable amounts of glucose and mannose was obtained by digestion with jack-bean oc-mannosidase and analysis of products on Bio-Gel P4. Oligosaccharide I is probably Glc3Man9GlcNAc, since mannosidase released 42 % of label as free mannose and produced a resistant fragment that was eluted from Bio-Gel P4 in the position (column fractions 65-70) described above for a Glc3Man5GlcNAc species (see Fig. 6a ). Similar treatment of oligosaccharides II, III and IV with jack-bean a.-mannosidase released free mannose and resistant oligosaccharide fragments that were eluted from Bio-Gel P4 in column fractions 65-70 and in a fraction (see Fig. 6a ) of lower size (column fraction 72-77). The relative proportion of radioactivity recovered in the small resistant fragment was greatest in oligosaccharide IV, where it was the major resistant component. Thus the available evidence suggests that the major component of oligosaccharide IV is probably Glc2Man7GlcNAc, III contains a mixture of Glc2Man8GlcNAc and Glc3Man7GlcNAc, and II contains probably a mixture of Glc2Man9GlcNAc and Glc3Man8GlcNAc. Effects of long-term treatments with inhibitors on asparagine-flinked oligosaccharides of BHK cells
In an attempt to induce more extreme effects of the inhibitors on oligosaccharide processing, experiments were performed in which cells were cultured continuously in media containing either 2 mM-dNM or 2 mM-dMM. The cells maintained full viability during such treatments, and no effects were detected on growth rate or plating efficiency after four successive sub-cultures (16) (17) (18) (19) (20) (Fig. 2) . In particular, formation of complex-type chains was not totally prevented. However, the effect of prolonged treatment with dMM was somewhat more pronounced than was obtained after short-term exposure, as shown by analysis of the oligosaccharides released from concanavalin A-Sepharose fraction C with endo-,8-Nacetylglucosaminidase H ( [1, 2] , were incubated with the plant toxins ricin and modeccin. These toxins bind to galactose residues of asparaginelinked oligosaccharides present in cell-surface glycoproteins, and this binding is a necessary first step in mediation of lectin cytotoxicity. As shown in Fig. 7 , the resistance of BHK cells to ricin, as measured by incorporation of [35S]methionine into total cellular proteins, was only marginally increased by pretreatment of the cells with the processing inhibitors. The protective effective against modeccin cytotoxicity was more significant. In both cases dMM produced the largest protective effect, consistent with the most profound inhibitory effect of this inhibitor on the assembly of complex-type asparagine-linked oligosaccharides containing galactose. Castanospermine gave the next most protection, whereas dNM gave little or no protection.
DISCUSSION
The present results show that treatment of BHK cells under various conditions with dNM or M-dNM influenced the composition of asparagine-linked oligosaccharides in bulk cellular glycoproteins but did not prevent formation of complex-type oligosaccharides. Both inhibitors induced accumulation of glucosylated oligomannose units as stable entities in glycoproteins without affecting the overall extent of bulk glycosylation, since the extent of incorporation of [3H]mannose into glycoproteins was similar over 1-2 days of labelling in the inhibitor-treated or control cells. Hence it can be excluded that in the inhibitor-treated cells we were measuring the glycosylation of a sub-set of cellular glycoproteins that under normal conditions also carried glucosylated carbohydrate chains.
On the basis of the preliminary structural information obtained with endo-,/-N-acetylglucosaminidase Hreleased material, M-dNM appears to induce accumulation of three oligosaccharides migrating more slowly than Man9GlcNAc in paper chromatography. Jack-bean a-mannosidase digestion of these oligosaccharides gave a major product with characteristics expected of the mannosidase-resistant fragment of Glc3Man9GlcNAc, producing Man,GIcNAc in significant amounts, indicates either that a low residual activity of glucosidases I and II persists or that alternative metabolic pathways operate which by-pass these enzyme activities. Assays in vitro have shown that glucosidase I is strongly inhibited by MdNM (50 % inhibition at 0.07 ,tM concentration) and less inhibited by dNM (1-3 /tM concentrations) whereas glucosidase II is inhibited only at concentrations above 20 /LM [8] [9] [10] . Although we would expect these concentrations to be reached by treatment of cells with 1-2 mm inhibitor, this may not be the case, especially for dNM. Evidence for transfer of non-glucosylated oligosaccharides to polypeptide has recently been reported in F9 teratocarcinoma cells exposed to M-dNM [24] . Our data obtained with dMM also show that extensive processing occurred in cells treated with this inhibitor. Several processing mannosidases specific for removal of al-*2-linked mannose residues of the Glc3Man9-GlcNAc2 precursor have been described in endoplasmic reticulum and Golgi membranes [2] . As shown by assays in vitro, dMM inhibits rat liver Golgi mannosidases IA and IB [12] and a calf liver microsomal Man9 mannosidase [13] at sub-micromolar concentrations. If these dMM-sensitive enzymes were maximally inhibited in BHK cells treated with 1-2 mm concentrations of dMM used in our experiments, the observed processing could involve an endoplasmic-reticulum mannosidase that, as Bischoff & Kornfeld [12] have shown, is not inhibited by dMM. In rat liver the endoplasmic-reticulum mannosidase is thought to remove specifically only one ac1-2-linked mannose residue from Man9GlcNAc2 [12, 25, 26] , although the solubilized enzyme shows a broader substrate specificity [26] , which in BHK cells may be expressed sufficiently to produce the extensive processing observed. However, the possible presence of additional dMM-insensitive mannosidases active on Man8GlcNAc and smaller oligomers cannot be excluded.
Several additional points arise from the analysis shown in Table 2 . First, the absolute concentrations of Man,GlcNAc and Man6GlcNAc are similar in control or dMM-treated cells, and hence the decreased amount of complex-type oligosaccharides in dMM-treated cells cannot be related simply to lack of a suitable substrate (Man,GlcNAc2) for enzymes involved in conversion of oligomannose-type units into complex-type chains. This assumes that the fully processed oligomannose units appear on nascent glycoproteins at appropriate intracellular sites containing the converting glycosyltranferases and that these latter enzymes are correctly positioned in dMM-treated cells, neither of which assumption may be true. However, it is clear that the major switch in dMM-treated cells involves the largersized oligomannose units. In dMM-treated cells the decrease in concentration of complex-type chains is balanced approximately by an increased concentration of Man9GlcNAc, Man8GlcNAc and Man7GlcNAc species (Table 2) . Presumably, since the greatest effect of dMM was observed on the concentration of the Man9-GlcNAc species (a 5-15-fold increase, Table 2 ), at least part of the initial processing of protein-linked MangGlcNAc2 involves a dMM-sensitive endoplasmicreticulum mannosidase and not the dMM-insensitive enzyme described by Bischoff& Kornfeld [12, 26] . Similar evidence for distinct processing pathways in rat liver were recently obtained by Bischoff et al. [25] . It is possible that processing of oligomannose units destined for conversion into complex-type chains may be different, involving separate enzymes, to the processing leading to stable oligomannose-type units of mature glycoproteins. If this speculation is correct, the data collected in Table 2 imply that in BHK cells approx. 30 % of complex-type oligosaccharides are assembled by a dMM-insensitive pathway, 50% are assembled by a pathway totally involving dMM-sensitive enzymes and 20 % are assembled by a pathway involving the dMM-insensitive enzyme converting Man9GlcNAc2 into Man8GlcNAc2 [12, 26] and dMM-sensitive processing mannosidases involved in further processing of the Man8GlcNAc2 intermediate.
The results described here obtained with inhibitors of processing glucosidases I and II (dNM and M-dNM) or mannosidases (dMM) are in striking contrast with an earlier study using swainsonine [3] . Swainsonine is an inhibitor of mannosidase II, which is responsible for hydrolysis of two mannose residues linked respectively al-+3 and al-*6 in the biosynthetic asparagine-linked intermediate GlcNAcMan5GlcNAc2, and is a key enzyme in conversion of oligomannose-type and hybridtype oligosaccharides into complex-type chains. Treatment of BHK cells with swainsonine was found to prevent completely formation of complex-type chains in bulk cellular glycoproteins, which were replaced quantitatively by hybrid-type chains. Cells bearing these modified carbohydrates were markedly more resistant to ricin cytotoxicity.
